Stock Events

Stock Events

RegeneRx Biopharmaceuticals

$0

0

+$0+0% Friday 21:22

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

10NovExpected

Q1 2022

Q2 2022

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

0

0

0.01

0.01

Expected EPS

0

Actual EPS

0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGRXD. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Apple Inc. competes in various technology sectors, overlapping with Gooi Global's interests in tech innovation and consumer electronics.

Alphabet Inc., through its various subsidiaries, competes directly in the digital services and technology solutions sectors.

Microsoft Corporation offers software, hardware, and cloud solutions that directly compete with some of Gooi Global's tech offerings.

Amazon.com Inc. competes with Gooi Global in e-commerce, cloud computing, and digital streaming services.

ProShares S&P 500 Dynamic Buffer

Meta Platforms Inc., formerly Facebook, competes in the social media and digital advertising markets.

Intel Corporation provides semiconductor chips, competing with Gooi Global in the technology hardware sector.

International Business Machines

International Business Machines Corporation offers cloud and cognitive solutions that compete with Gooi Global's tech services.

Cisco Systems, Inc. provides networking hardware, software, and telecommunications equipment that competes with Gooi Global's technology solutions.

Oracle Corporation offers database software and technology, cloud engineered systems, and enterprise software products that compete in the tech market.

HP Inc. competes in the personal computing and printing businesses, overlapping with Gooi Global's interests in consumer tech products.

About

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Show more...

CEO

ISIN

US75886X3061

Listings

0 Comments

Share your thoughts

FAQ

What is RegeneRx Biopharmaceuticals stock price today?▼

The current price of RGRXD is $0 USD — it has increased by +0% in the past 24 hours. Watch RegeneRx Biopharmaceuticals stock price performance more closely on the chart.

What is RegeneRx Biopharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange RegeneRx Biopharmaceuticals stocks are traded under the ticker RGRXD.

What were RegeneRx Biopharmaceuticals earnings last quarter?▼

RGRXD earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.

When did RegeneRx Biopharmaceuticals complete a stock split?▼

RegeneRx Biopharmaceuticals has not had any recent stock splits.